| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration revenue | 13,782 | 14,245 | 16,627 | 9,111 |
| Research and development | 94,747 | 97,035 | 108,427 | 123,380 |
| General and administrative | 30,512 | 27,206 | 29,007 | 30,501 |
| Total operating expenses | 125,259 | 124,241 | 137,434 | 153,881 |
| Operating loss | -111,477 | -109,996 | -120,807 | -144,770 |
| Interest income | 6,714 | 7,402 | 8,603 | 12,122 |
| Change in fair value of investments, net | 3,439 | 1,339 | -2,125 | -3,064 |
| Total other income, net | 10,153 | 8,741 | 6,478 | 9,058 |
| Net loss | -101,324 | -101,255 | -114,329 | -135,712 |
| Unrealized gain on marketable securities | 337 | -404 | 452 | 4,452 |
| Comprehensive loss | -100,987 | -101,659 | -113,877 | -131,260 |
| Net loss per share, basic | -0.92 | -0.98 | -1.1 | -1.34 |
| Net loss per share, diluted | -0.92 | -0.98 | -1.1 | -1.34 |
| Weighted average shares outstanding, basic | 110,188,000 | 103,732,000 | 103,500,000 | 101,002,000 |
| Weighted average shares outstanding, diluted | 110,188,000 | 103,732,000 | 103,500,000 | 101,002,000 |
Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. (NTLA)